S.Biomedics’ Parkinson's Cell Therapy Shows Early Clinical Promise
Expectations Rise For High-Dose Data
A novel stem cell therapy for Parkinson’s disease developed by a Korean firm has shown what Citeline analysts describe as "very promising" early clinical results at a low dose after one year.
